Cutaneous melanocytic lesions present some of the most intricate diagnostic challenges in modern dermatopathology. Among these challenging proliferations, SPARK nevi represent a distinct histological phenomenon defined by the union of Spitzoid cytomorphology and Clark-type or dysplastic architectural patterns. Because these compound lesions display marked architectural disorder alongside cytological enlargement, clinicians and pathologists frequently struggle to distinguish them from superficial spreading melanoma or atypical Spitz tumors. Consequently, accurate characterization is essential to prevent overtreatment. A comprehensive multi-institutional study across six academic centers recently evaluated 74 cases to establish clear diagnostic criteria and clarify the biologic behavior of these uncommon neoplasms.

Understanding the Histopathologic Dualism of SPARK Nevi

The term SPARK represents an acronym reflecting Spitzoid cytology in a Clark-type nevus architecture. Historically, pathologists often found these conflicting features difficult to reconcile. In the recent multi-institutional cohort, seventy percent of all identified lesions were compound melanocytic nevi. Microscopically, these proliferations demonstrate elongated epidermal rete ridges, architectural bridging between adjacent rete, and variable lamellar fibroplasia in the papillary dermis. These architectural findings precisely mirror classic dysplastic nevi. However, high-power examination reveals large, epithelioid or spindled melanocytes with abundant cytoplasm and prominent nucleoli characteristic of Spitz nevi. In this multi-center series, forty-seven percent exhibited mixed epithelioid-spindled morphology, whereas forty-one percent showed purely epithelioid features. Interestingly, Kamino bodies appeared in only nine percent of specimens. Thus, recognizing this cytologic and architectural dualism prevents unnecessary classification as malignant melanoma.

Key Demographic and Clinical Characteristics of SPARK Nevi

Clinicians encounter these atypical melanocytic lesions across a wide demographic range, though clear epidemiological patterns have emerged. The multi-institutional study demonstrated a prominent female predominance, accounting for seventy-six percent of all confirmed cases. Furthermore, the mean patient age at presentation was 32.4 years, spanning an age range between 11 and 68 years. Clinically, these lesions present as small, pigmented macules or thin plaques with irregular borders and variable color variegation. The mean diameter documented in the cohort was 5.8 millimeters, with lesions ranging from 2 to 20 millimeters. Most lesions occurred on the trunk and proximal extremities. Because dermoscopic examination frequently reveals atypical network patterns with focal pigment asymmetry, dermatologists routinely excise these nevi to rule out early malignancy. Consequently, clinical awareness of their typical anatomical distribution assists in comprehensive diagnostic evaluation.

Diagnostic Immunohistochemistry and Biomarker Profiling

Immunohistochemical analysis provides indispensable objective evidence when evaluating morphologically borderline melanocytic proliferations. In the analyzed multi-center cohort, fifty-five percent of cases underwent diagnostic immunohistochemistry to confirm benign lineage. Notably, all evaluated lesions showed negative expression for PRAME (Preferentially Expressed Antigen in Melanoma), which serves as a highly sensitive surrogate marker for cutaneous melanoma. Additionally, p16 expression was universally retained across the dermal and junctional nests, confirming intact cell-cycle regulation and the absence of CDKN2A homozygous deletions. Furthermore, MKI67 proliferation indices remained consistently low, typically below two to five percent, localized strictly to the junctional component. Therefore, this triad of PRAME negativity, retained p16 expression, and minimal mitotic activity provides strong reassurance when cytological atypia appears moderate to severe.

Differential Diagnosis and Overlap with Malignant Melanoma

Distinguishing these composite lesions from true melanocytic malignancies remains paramount in routine practice. Pathologists must carefully differentiate between reactive Spitzoid atypia and the severe nuclear pleomorphism seen in melanoma. Unlike superficial spreading melanoma, these nevi preserve architectural symmetry, lateral circumscription, and appropriate maturation of dermal melanocytes with increasing depth. Moreover, pagetoid melanocytic scatter remains strictly confined to the lower epidermal tiers and the center of the lesion, avoiding the diffuse upward scatter typical of melanoma. Brisk inflammatory infiltrates are generally absent; in fact, sixty-two percent of cases in the cohort displayed only non-brisk or absent lymphocytic inflammation. Furthermore, genomic and morphological analyses confirm that these lesions represent a benign pattern rather than a single distinct molecular entity, arising through diverse melanocytic signaling pathways.

Long-Term Biologic Behavior and Clinical Management

Understanding the long-term clinical outcome of these nevi is critical for avoiding aggressive and disfiguring surgical interventions. In the multi-institutional series, clinical follow-up was achieved for ninety-three percent of patients, with a median follow-up interval of 18 months. Reassuringly, the study recorded zero disease-related deaths and no regional or distant lymph node metastases. Only one patient developed a mild local recurrence following an initial shave biopsy with positive margins, and two patients developed metachronous lesions at unrelated cutaneous sites. Consequently, complete conservative surgical excision with clear histological margins remains the definitive and sufficient treatment standard. Routine sentinel lymph node biopsy is completely unnecessary. Therefore, clear interdisciplinary communication between dermatologists and pathologists ensures conservative management while maintaining patient safety.

Frequently Asked Questions

What defining histological features distinguish SPARK nevi from standard dysplastic nevi?

SPARK nevi uniquely combine the architectural blueprint of a dysplastic Clark nevus with the distinct cytology of a Spitz nevus. While standard dysplastic nevi contain smaller melanocytes with delicate nesting and bridging, these composite lesions showcase large, epithelioid or spindled melanocytes with abundant eosinophilic cytoplasm, prominent nucleoli, and significant nuclear enlargement, requiring careful diagnostic differentiation.

Which immunohistochemical markers best help rule out cutaneous melanoma in these lesions?

Immunohistochemistry utilizing PRAME, p16, and Ki-67 (MKI67) offers high diagnostic specificity. These benign compound nevi consistently demonstrate negative nuclear PRAME staining, robust and retained p16 expression, and very low Ki-67 proliferation indices. Conversely, malignant melanomas frequently exhibit diffuse PRAME positivity, complete loss of p16, and markedly elevated mitotic rates extending deep into the dermis.

What is the recommended surgical management for a confirmed SPARK nevus?

Complete conservative surgical excision with narrow, clear histological margins represents the standard of care for these lesions. Because long-term follow-up confirms entirely benign biologic behavior without risk of metastatic spread, aggressive re-excisions, wide safety margins, and sentinel lymph node biopsies are completely unnecessary, ensuring excellent cosmetic and clinical outcomes for affected patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Clinical decisions should be guided by qualified healthcare professionals based on individual patient circumstances. Refer to the latest local and national guidelines for clinical practice.

References

• El-Rayes D et al. Histopathology and Clinical Features of SPARK Nevi in a Multi-Institutional Cohort. Int J Surg Pathol. 2026 Aug 14. doi: 10.1177/10668969261466611. PMID: 42599278.


• Ko CJ, McNiff JM, Glusac EJ. Melanocytic nevi with features of Spitz nevi and Clark's/dysplastic nevi ("Spark's" nevi). J Cutan Pathol. 2009;36(10):1063-1068.


• Massone C, Biondo G, Gnone M, Sola S, Pastorino C. Dermoscopy of a Spark's nevus. Dermatol Pract Concept. 2018;8(2):107-109.


• Zhao J, Benton S, Zhang B, et al. Benign and Intermediate-grade Melanocytic Tumors With BRAF Mutations and Spitzoid Morphology. Am J Surg Pathol. 2022;46(4):476-485.